XML 14 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue $ 10,549 $ 0 $ 38,728 $ 0
Cost of goods sold 9,426 0 32,300 0
Gross margin 1,123 0 6,428 0
Operating expenses:        
Research and development 2,346 4,533 6,066 13,753
General and administrative 3,447 1,578 13,716 4,169
Total operating expenses 5,793 6,111 19,782 17,922
Loss from operations (4,670) (6,111) (13,354) (17,922)
Other income (loss):        
Interest income 124 250 2,328 379
Other income (loss) 0 0 (503) 10
Foreign exchange gain (loss) 1,352 (289) 794 (333)
Total other income (loss) 1,476 (39) 2,619 56
Loss before income taxes (3,194) (6,150) (10,735) (17,866)
Benefit for income taxes (668) 0 (1,352) 0
Net loss $ (2,526) $ (6,150) $ (9,383) $ (17,866)
Net loss per share—basic and diluted (in dollars per share) $ (0.09) $ (0.15) $ (0.30) $ (0.47)
Shares used to compute basic net loss per share (in shares) 29,037,074 41,019,230 31,345,760 38,190,584
Manufacturing Revenue [Member]        
Revenue $ 6,000 $ 0 $ 13,500 $ 0
Cost of goods sold 5,432 0 11,553 0
Clinical Trial Service Revenue [Member]        
Revenue 4,549 0 25,228 0
Cost of goods sold $ 3,994 $ 0 $ 20,747 $ 0